ADC Therapeutics to Host Fourth Quarter and Year-End 2021 Financial Results Conference Call on March 3, 2022

Rhea-AI Summary

ADC Therapeutics (NYSE: ADCT) will host a conference call on March 3, 2022, at 8:30 a.m. ET to discuss its Q4 and year-end 2021 financial results and provide business updates. This call aims to inform investors about the company's performance and strategic direction. ADC Therapeutics specializes in targeted antibody drug conjugates for cancer treatment, with an FDA-approved product, ZYNLONTA®, for specific lymphoma treatments. The presentation will be available live and archived on their investor website.

Positive

• ADC Therapeutics specializes in innovative antibody drug conjugates for cancer.
• The FDA has approved ZYNLONTA® for treating specific types of lymphoma.

Negative

• None.

LAUSANNE, Switzerland--(BUSINESS WIRE)-- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, today announced that it will host a conference call and live webcast on Thursday, March 3, 2022 at 8:30 a.m. ET to report financial results for the fourth quarter and year-end 2021 and provide business updates.

To access the live call, please dial 833-303-1198 (domestic) or +1 914-987-7415 (international) and provide conference ID 8189237. A live webcast of the presentation will be available under “Events and Presentations” in the Investors section of the ADC Therapeutics website at ir.adctherapeutics.com. The archived webcast will be available for 30 days following the call.

About ADC Therapeutics

ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs). The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

ADC Therapeutics’ CD19-directed ADC ZYNLONTA® (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large b-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents. Cami (camidanlumab tesirine) is being evaluated in a pivotal Phase 2 trial for relapsed or refractory Hodgkin lymphoma and in a Phase 1b clinical trial for various advanced solid tumors. In addition to ZYNLONTA and Cami, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.

ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit https://adctherapeutics.com/ and follow the Company on Twitter and LinkedIn.

ZYNLONTA® is a registered trademark of ADC Therapeutics SA.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220224005180/en/

Investors

Eugenia Litz

ADC Therapeutics

Eugenia.Litz@adctherapeutics.com

Tel.: +44 7879 627205



Amanda Hamilton

ADC Therapeutics

amanda.hamilton@adctherapeutics.com

Tel.: +1 917 288 7023



EU Media

Alexandre Müller

Dynamics Group

amu@dynamicsgroup.ch

Tel: +41 (0) 43 268 3231



USA Media

Mary Ann Ondish

ADC Therapeutics

maryann.ondish@adctherapeutics.com

Tel.: +1 914-552-4625

Source: ADC Therapeutics SA

FAQ

When is ADC Therapeutics' next financial results conference call?

ADC Therapeutics will host its next financial results conference call on March 3, 2022, at 8:30 a.m. ET.

What is ZYNLONTA® used for?

ZYNLONTA® is FDA-approved for treating relapsed or refractory diffuse large b-cell lymphoma after two or more lines of systemic therapy.

How can I access the live webcast of ADC Therapeutics' conference call?

The live webcast can be accessed through the 'Events and Presentations' section on the ADC Therapeutics investor website.

What does ADC Therapeutics focus on?

ADC Therapeutics focuses on developing next-generation targeted antibody drug conjugates for treating cancer.